AUROPHARMA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Aurobindo Pharma Says Small Fire Incident Occurred In Granulation Area-10 Of Unit IV Of APL Healthcare
Sept 19 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
AUROBINDO PHARMA - SMALL FIRE INCIDENT OCCURRED IN GRANULATION AREA-10 OF UNIT IV OF APL HEALTHCARE
AUROBINDO PHARMA LTD - 2 LINES IMPACTED FOR ABOUT TWO WEEKS
AUROBINDO PHARMA LTD - NO CASUALTIES OR INJURIES REPORTED
AUROBINDO PHARMA LTD - TEMPORARY PRODUCTION IMPACT ESTIMATED AT 3% OF CAPACITY
AUROBINDO PHARMA LTD - REFURBISHMENT INITIATED, OPERATIONAL IN NEXT FEW WEEKS
Source text: [ID:]
Further company coverage: ARBN.NS
(([email protected];))
Sept 19 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
AUROBINDO PHARMA - SMALL FIRE INCIDENT OCCURRED IN GRANULATION AREA-10 OF UNIT IV OF APL HEALTHCARE
AUROBINDO PHARMA LTD - 2 LINES IMPACTED FOR ABOUT TWO WEEKS
AUROBINDO PHARMA LTD - NO CASUALTIES OR INJURIES REPORTED
AUROBINDO PHARMA LTD - TEMPORARY PRODUCTION IMPACT ESTIMATED AT 3% OF CAPACITY
AUROBINDO PHARMA LTD - REFURBISHMENT INITIATED, OPERATIONAL IN NEXT FEW WEEKS
Source text: [ID:]
Further company coverage: ARBN.NS
(([email protected];))
Private equity firm Advent to sell generic drugmaker Zentiva to GTCR
Adds deal value from source in paragraph 2, background on Zentiva and previous deal reports from paragraph 4 onwards
Sept 11 (Reuters) - Czech generic drugmaker Zentiva 1SKF401E.BV said on Thursday that private equity group Advent International had agreed to sell the company to rival GTCR for an undisclosed value.
The deal values the Prague-based company at slightly more than 4 billion euros ($4.69 billion) including debt, according to a source with knowledge of the deal.
The Financial Times had first reported the deal on Wednesday, saying it was worth 4.1 billion euros.
Zentiva was acquired by Advent from French pharmaceutical giant Sanofi SASY.PA in 2018 for an enterprise value of 1.9 billion euros.
There have been reports of Advent mulling a sale of the generics drugmaker since 2021, with companies such as Polish drugmaker Polpharma and India's Aurobindo Pharma ARBN.NS reported to be joining the race.
Zentiva supplies a wide range of generic and over-the-counter drugs such as paracetamol and co-codamol to more than 100 million people across Europe.
($1 = 0.8530 euros)
(Reporting by Unnamalai L in Bengaluru and Andres Gonzalez Estebaran; Editing by Maju Samuel)
(([email protected];))
Adds deal value from source in paragraph 2, background on Zentiva and previous deal reports from paragraph 4 onwards
Sept 11 (Reuters) - Czech generic drugmaker Zentiva 1SKF401E.BV said on Thursday that private equity group Advent International had agreed to sell the company to rival GTCR for an undisclosed value.
The deal values the Prague-based company at slightly more than 4 billion euros ($4.69 billion) including debt, according to a source with knowledge of the deal.
The Financial Times had first reported the deal on Wednesday, saying it was worth 4.1 billion euros.
Zentiva was acquired by Advent from French pharmaceutical giant Sanofi SASY.PA in 2018 for an enterprise value of 1.9 billion euros.
There have been reports of Advent mulling a sale of the generics drugmaker since 2021, with companies such as Polish drugmaker Polpharma and India's Aurobindo Pharma ARBN.NS reported to be joining the race.
Zentiva supplies a wide range of generic and over-the-counter drugs such as paracetamol and co-codamol to more than 100 million people across Europe.
($1 = 0.8530 euros)
(Reporting by Unnamalai L in Bengaluru and Andres Gonzalez Estebaran; Editing by Maju Samuel)
(([email protected];))
Aurobindo Pharma Says US FDA Completes Inspection At Unit-XII
Sept 5 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
AUROBINDO PHARMA - COMPLETION OF US FDA INSPECTION AT UNIT-XII OF AUROBINDO PHARMA
AUROBINDO PHARMA - TOTAL OF 8 OBSERVATIONS ISSUED BY FDA
Source text: [ID:]
Further company coverage: ARBN.NS
(([email protected];;))
Sept 5 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
AUROBINDO PHARMA - COMPLETION OF US FDA INSPECTION AT UNIT-XII OF AUROBINDO PHARMA
AUROBINDO PHARMA - TOTAL OF 8 OBSERVATIONS ISSUED BY FDA
Source text: [ID:]
Further company coverage: ARBN.NS
(([email protected];;))
Health Rounds: Clopidogrel better than aspirin for preventing heart attacks and strokes
This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here
By Nancy Lapid
Sept 3 (Reuters) - The commonly prescribed blood thinner clopidogrel should replace aspirin as a routine pill for preventing heart attacks and strokes in people who already have at least some degree of heart disease, researchers reported at the European Society of Cardiology Congress.
Pooled data on nearly 29,000 patients with coronary artery disease who had participated in seven earlier randomized trials showed that those taking clopidogrel had a 14% lower risk of major adverse cardiovascular or cerebrovascular events, including heart attack, stroke, or cardiovascular death, compared to those taking aspirin, during an average follow-up of 5.5 years.
“These results suggest that clopidogrel should be considered the preferred long-term antiplatelet medication for patients with established coronary artery disease,” the researchers said.
Clopidogrel is the generic name of the widely used blood clot preventer Plavix, sold by Bristol Myers Squibb BMY.N and Sanofi SASY.PA. Several companies sell generic clopidogrel including Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS and Teva Pharmaceuticals TEVA.TA.
Rates of anticoagulant-related side effects like ulcers and major bleeding were similar between the two drugs, dispelling concerns that clopidogrel might lead to more bleeding complications, the researchers said.
The researchers said their analysis included many types of patients and subgroups to ensure the findings, which were also published in The Lancet, applied broadly.
“Even patients who might respond less well to clopidogrel due to genetic or clinical factors still benefited from its use over aspirin,” the researchers said in a statement.
Because clopidogrel is widely available and inexpensive, the study’s findings have the potential to influence clinical guidelines worldwide and improve patient outcomes, the researchers said.
RECYCLED PACEMAKERS IMPROVE ACCESS IN LOW-INCOME NATIONS
Cardiac pacemaker devices can be reconditioned to provide new hope for patients in low- and middle-income countries, researchers said at the ESC meeting in Madrid.
In Kenya, Mexico, Mozambique, Nigeria, Paraguay, Sierra Leone and Venezuela, 306 patients with a life expectancy of at least two years, a clear medical need for pacemaker therapy and no financial means to acquire one were randomly assigned to receive a reconditioned pacemaker or a new pacemaker.
The researchers’ primary concern was that reconditioned devices, which had been removed from other patients, might transmit infections when re-implanted.
A year after the pacemakers were implanted, the incidence of procedure-related infections was 1.6% for those in the reconditioned pacemaker group and 3.1% for those who got new devices. The results demonstrate that the older devices were non-inferior to new ones, the researchers said in a statement.
There were no device malfunctions in either group.
The study was conducted by doctors at the University of Michigan-based Project My Heart Your Heart, which collects pacemakers removed from cadavers by funeral directors.
“Patients in many low- and middle-income countries still have very limited access to cardiac pacing despite its routine use in higher-income countries,” study leader Dr. Thomas Crawford from the University of Michigan said in a statement.
“Indeed, access to pacemaker implantation is around 200-fold lower in Africa than in Europe," Crawford said.
Project My Heart Your Heart developed a comprehensive protocol for cleaning, functional testing and sterilizing reconditioned devices, and has U.S. approval for their export to countries whose governments have provided permission for pacemaker importation, he added.
(To receive the full newsletter in your inbox for free sign up here)
(Reporting by Nancy Lapid; Editing by Bill Berkrot)
This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays. To receive the full newsletter in your inbox for free sign up here
By Nancy Lapid
Sept 3 (Reuters) - The commonly prescribed blood thinner clopidogrel should replace aspirin as a routine pill for preventing heart attacks and strokes in people who already have at least some degree of heart disease, researchers reported at the European Society of Cardiology Congress.
Pooled data on nearly 29,000 patients with coronary artery disease who had participated in seven earlier randomized trials showed that those taking clopidogrel had a 14% lower risk of major adverse cardiovascular or cerebrovascular events, including heart attack, stroke, or cardiovascular death, compared to those taking aspirin, during an average follow-up of 5.5 years.
“These results suggest that clopidogrel should be considered the preferred long-term antiplatelet medication for patients with established coronary artery disease,” the researchers said.
Clopidogrel is the generic name of the widely used blood clot preventer Plavix, sold by Bristol Myers Squibb BMY.N and Sanofi SASY.PA. Several companies sell generic clopidogrel including Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS and Teva Pharmaceuticals TEVA.TA.
Rates of anticoagulant-related side effects like ulcers and major bleeding were similar between the two drugs, dispelling concerns that clopidogrel might lead to more bleeding complications, the researchers said.
The researchers said their analysis included many types of patients and subgroups to ensure the findings, which were also published in The Lancet, applied broadly.
“Even patients who might respond less well to clopidogrel due to genetic or clinical factors still benefited from its use over aspirin,” the researchers said in a statement.
Because clopidogrel is widely available and inexpensive, the study’s findings have the potential to influence clinical guidelines worldwide and improve patient outcomes, the researchers said.
RECYCLED PACEMAKERS IMPROVE ACCESS IN LOW-INCOME NATIONS
Cardiac pacemaker devices can be reconditioned to provide new hope for patients in low- and middle-income countries, researchers said at the ESC meeting in Madrid.
In Kenya, Mexico, Mozambique, Nigeria, Paraguay, Sierra Leone and Venezuela, 306 patients with a life expectancy of at least two years, a clear medical need for pacemaker therapy and no financial means to acquire one were randomly assigned to receive a reconditioned pacemaker or a new pacemaker.
The researchers’ primary concern was that reconditioned devices, which had been removed from other patients, might transmit infections when re-implanted.
A year after the pacemakers were implanted, the incidence of procedure-related infections was 1.6% for those in the reconditioned pacemaker group and 3.1% for those who got new devices. The results demonstrate that the older devices were non-inferior to new ones, the researchers said in a statement.
There were no device malfunctions in either group.
The study was conducted by doctors at the University of Michigan-based Project My Heart Your Heart, which collects pacemakers removed from cadavers by funeral directors.
“Patients in many low- and middle-income countries still have very limited access to cardiac pacing despite its routine use in higher-income countries,” study leader Dr. Thomas Crawford from the University of Michigan said in a statement.
“Indeed, access to pacemaker implantation is around 200-fold lower in Africa than in Europe," Crawford said.
Project My Heart Your Heart developed a comprehensive protocol for cleaning, functional testing and sterilizing reconditioned devices, and has U.S. approval for their export to countries whose governments have provided permission for pacemaker importation, he added.
(To receive the full newsletter in your inbox for free sign up here)
(Reporting by Nancy Lapid; Editing by Bill Berkrot)
Health Rounds: Clopidogrel better than aspirin for preventing heart attacks and strokes
Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here
By Nancy Lapid
Sept 2 (Reuters) - Hello Health Rounds readers! Today we highlight two studies presented at the European Society of Cardiology meeting in Madrid, one that compared widely used blood thinners for preventing serious heart problems, and one that tested the safety of reusing cardiac pacemakers.
Clopidogrel tops aspirin for routine use in heart patients
The commonly prescribed blood thinner clopidogrel should replace aspirin as a routine pill for preventing heart attacks and strokes in people who already have at least some degree of heart disease, researchers reported at the European Society of Cardiology Congress.
Pooled data on nearly 29,000 patients with coronary artery disease who had participated in seven earlier randomized trials showed that those taking clopidogrel had a 14% lower risk of major adverse cardiovascular or cerebrovascular events, including heart attack, stroke, or cardiovascular death, compared to those taking aspirin, during an average follow-up of 5.5 years.
“These results suggest that clopidogrel should be considered the preferred long-term antiplatelet medication for patients with established coronary artery disease,” the researchers said.
Clopidogrel is the generic name of the widely used blood clot preventer Plavix, sold by Bristol Myers Squibb BMY.N and Sanofi SASY.PA. Several companies sell generic clopidogrel including Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS and Teva Pharmaceuticals TEVA.TA.
Rates of anticoagulant-related side effects like ulcers and major bleeding were similar between the two drugs, dispelling concerns that clopidogrel might lead to more bleeding complications, the researchers said.
The researchers said their analysis included many types of patients and subgroups to ensure the findings, which were also published in The Lancet, applied broadly.
“Even patients who might respond less well to clopidogrel due to genetic or clinical factors still benefited from its use over aspirin,” the researchers said in a statement.
Because clopidogrel is widely available and inexpensive, the study’s findings have the potential to influence clinical guidelines worldwide and improve patient outcomes, the researchers said.
Recycled pacemakers improve access in low-income nations
Cardiac pacemaker devices can be reconditioned to provide new hope for patients in low- and middle-income countries, researchers said at the ESC meeting in Madrid.
In Kenya, Mexico, Mozambique, Nigeria, Paraguay, Sierra Leone and Venezuela, 306 patients with a life expectancy of at least two years, a clear medical need for pacemaker therapy and no financial means to acquire one were randomly assigned to receive a reconditioned pacemaker or a new pacemaker.
The researchers’ primary concern was that reconditioned devices, which had been removed from other patients, might transmit infections when re-implanted.
A year after the pacemakers were implanted, the incidence of procedure-related infections was 1.6% for those in the reconditioned pacemaker group and 3.1% for those who got new devices. The results demonstrate that the older devices were non-inferior to new ones, the researchers said in a statement.
There were no device malfunctions in either group.
The study was conducted by doctors at the University of Michigan-based Project My Heart Your Heart, which collects pacemakers removed from cadavers by funeral directors.
“Patients in many low- and middle-income countries still have very limited access to cardiac pacing despite its routine use in higher-income countries,” study leader Dr. Thomas Crawford from the University of Michigan said in a statement.
“Indeed, access to pacemaker implantation is around 200-fold lower in Africa than in Europe," Crawford said.
Project My Heart Your Heart developed a comprehensive protocol for cleaning, functional testing and sterilizing reconditioned devices, and has U.S. approval for their export to countries whose governments have provided permission for pacemaker importation, he added.
(Reporting by Nancy Lapid; Editing by Bill Berkrot)
Health Rounds is published on Tuesdays and Thursdays. Think your friend or colleague should know about us? Forward this newsletter to them. They can also subscribe here
By Nancy Lapid
Sept 2 (Reuters) - Hello Health Rounds readers! Today we highlight two studies presented at the European Society of Cardiology meeting in Madrid, one that compared widely used blood thinners for preventing serious heart problems, and one that tested the safety of reusing cardiac pacemakers.
Clopidogrel tops aspirin for routine use in heart patients
The commonly prescribed blood thinner clopidogrel should replace aspirin as a routine pill for preventing heart attacks and strokes in people who already have at least some degree of heart disease, researchers reported at the European Society of Cardiology Congress.
Pooled data on nearly 29,000 patients with coronary artery disease who had participated in seven earlier randomized trials showed that those taking clopidogrel had a 14% lower risk of major adverse cardiovascular or cerebrovascular events, including heart attack, stroke, or cardiovascular death, compared to those taking aspirin, during an average follow-up of 5.5 years.
“These results suggest that clopidogrel should be considered the preferred long-term antiplatelet medication for patients with established coronary artery disease,” the researchers said.
Clopidogrel is the generic name of the widely used blood clot preventer Plavix, sold by Bristol Myers Squibb BMY.N and Sanofi SASY.PA. Several companies sell generic clopidogrel including Aurobindo Pharma ARBN.NS, Sun Pharma SUN.NS and Teva Pharmaceuticals TEVA.TA.
Rates of anticoagulant-related side effects like ulcers and major bleeding were similar between the two drugs, dispelling concerns that clopidogrel might lead to more bleeding complications, the researchers said.
The researchers said their analysis included many types of patients and subgroups to ensure the findings, which were also published in The Lancet, applied broadly.
“Even patients who might respond less well to clopidogrel due to genetic or clinical factors still benefited from its use over aspirin,” the researchers said in a statement.
Because clopidogrel is widely available and inexpensive, the study’s findings have the potential to influence clinical guidelines worldwide and improve patient outcomes, the researchers said.
Recycled pacemakers improve access in low-income nations
Cardiac pacemaker devices can be reconditioned to provide new hope for patients in low- and middle-income countries, researchers said at the ESC meeting in Madrid.
In Kenya, Mexico, Mozambique, Nigeria, Paraguay, Sierra Leone and Venezuela, 306 patients with a life expectancy of at least two years, a clear medical need for pacemaker therapy and no financial means to acquire one were randomly assigned to receive a reconditioned pacemaker or a new pacemaker.
The researchers’ primary concern was that reconditioned devices, which had been removed from other patients, might transmit infections when re-implanted.
A year after the pacemakers were implanted, the incidence of procedure-related infections was 1.6% for those in the reconditioned pacemaker group and 3.1% for those who got new devices. The results demonstrate that the older devices were non-inferior to new ones, the researchers said in a statement.
There were no device malfunctions in either group.
The study was conducted by doctors at the University of Michigan-based Project My Heart Your Heart, which collects pacemakers removed from cadavers by funeral directors.
“Patients in many low- and middle-income countries still have very limited access to cardiac pacing despite its routine use in higher-income countries,” study leader Dr. Thomas Crawford from the University of Michigan said in a statement.
“Indeed, access to pacemaker implantation is around 200-fold lower in Africa than in Europe," Crawford said.
Project My Heart Your Heart developed a comprehensive protocol for cleaning, functional testing and sterilizing reconditioned devices, and has U.S. approval for their export to countries whose governments have provided permission for pacemaker importation, he added.
(Reporting by Nancy Lapid; Editing by Bill Berkrot)
Aurobindo Pharma Ltd - Curateq Biologics Receives Mhra Approval For Dazulbys
Aug 26 (Reuters) - Aurobindo Pharma ARBN.NS:
CURATEQ BIOLOGICS RECEIVES MHRA APPROVAL FOR DAZULBYS
Source text: ID:nNSE1Ys71d
Further company coverage: ARBN.NS
(([email protected];))
Aug 26 (Reuters) - Aurobindo Pharma ARBN.NS:
CURATEQ BIOLOGICS RECEIVES MHRA APPROVAL FOR DAZULBYS
Source text: ID:nNSE1Ys71d
Further company coverage: ARBN.NS
(([email protected];))
India's Aurobindo Pharma recoups losses after saying no binding agreement for Zentiva
** Aurobindo Pharma ARBN.NS shares down 3.7 % at 1049.30 rupees, trimming earlier losses, after co says media reports on Zentiva deal "premature"
** Shares fell as much as 4.6% earlier in the session, their lowest since April 9, after reports said co was the front-runner to buy Prague-based Zentiva ROSCD.BX for $5.5 bln
** ARBN says no binding agreement or definitive decision has been made about the deal
** Around 3 mln shares traded, almost 2.7x their 30-day avg
** Twenty-six analysts covering ARBN have a "buy" rating on average; median PT is 1,300 rupees, per LSEG data
** As of Tuesday's close, stock is down ~20% YTD
(Reporting by Urvi Dugar)
** Aurobindo Pharma ARBN.NS shares down 3.7 % at 1049.30 rupees, trimming earlier losses, after co says media reports on Zentiva deal "premature"
** Shares fell as much as 4.6% earlier in the session, their lowest since April 9, after reports said co was the front-runner to buy Prague-based Zentiva ROSCD.BX for $5.5 bln
** ARBN says no binding agreement or definitive decision has been made about the deal
** Around 3 mln shares traded, almost 2.7x their 30-day avg
** Twenty-six analysts covering ARBN have a "buy" rating on average; median PT is 1,300 rupees, per LSEG data
** As of Tuesday's close, stock is down ~20% YTD
(Reporting by Urvi Dugar)
India's Aurobindo Pharma drops on quarterly profit fall
** Shares of Aurobindo Pharma ARBN.NS fall as much as 2.7% to 1060.90 rupees
** Pharma co posts 10% y/y drop in June-qtr consol net PAT, expenses rise 5%
** ARBN rev rose 4% but missed analysts' expectations of Macquarie and Motilal Oswal
** Macquarie said revenue miss was driven by lower than expected revenue from the U.S. business
** Adds, muted growth in co's "bread and butter" U.S. business worrisome
** More than 2.5 mln shares traded, 2x their 30-day avg
** Stock last down 1%, taking YTD losses to 18%
(Reporting by Nishit Navin in Bengaluru)
** Shares of Aurobindo Pharma ARBN.NS fall as much as 2.7% to 1060.90 rupees
** Pharma co posts 10% y/y drop in June-qtr consol net PAT, expenses rise 5%
** ARBN rev rose 4% but missed analysts' expectations of Macquarie and Motilal Oswal
** Macquarie said revenue miss was driven by lower than expected revenue from the U.S. business
** Adds, muted growth in co's "bread and butter" U.S. business worrisome
** More than 2.5 mln shares traded, 2x their 30-day avg
** Stock last down 1%, taking YTD losses to 18%
(Reporting by Nishit Navin in Bengaluru)
Aurobindo Pharma Q1 Consol Net Profit 8.25 Bln Rupees
Aug 4 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
Q1 CONSOL NET PROFIT 8.25 BILLION RUPEES
Q1 CONSOL TOTAL REVENUE FROM OPERATIONS 78.68 BILLION RUPEES
DIVIDEND 4 RUPEES PER SHARE
Further company coverage: ARBN.NS
(([email protected];;))
Aug 4 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
Q1 CONSOL NET PROFIT 8.25 BILLION RUPEES
Q1 CONSOL TOTAL REVENUE FROM OPERATIONS 78.68 BILLION RUPEES
DIVIDEND 4 RUPEES PER SHARE
Further company coverage: ARBN.NS
(([email protected];;))
Aurobindo Pharma Clarifies Report Trump Shoots Letters To Global Drug Majors
Aug 1 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
AUROBINDO PHARMA - CLARIFIES REPORT TRUMP SHOOTS LETTERS TO GLOBAL DRUG MAJORS
AUROBINDO PHARMA - NOT RECEIVED ANY COMMUNICATION AS PER MEDIA
Source text: ID:nBSEbwpshz
Further company coverage: ARBN.NS
(([email protected];))
Aug 1 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
AUROBINDO PHARMA - CLARIFIES REPORT TRUMP SHOOTS LETTERS TO GLOBAL DRUG MAJORS
AUROBINDO PHARMA - NOT RECEIVED ANY COMMUNICATION AS PER MEDIA
Source text: ID:nBSEbwpshz
Further company coverage: ARBN.NS
(([email protected];))
Aurobindo Pharma To Buy 100% Interest In Lannett Seller Holdco
July 30 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
AUROBINDO PHARMA LTD - TO BUY 100% INTEREST IN LANNETT SELLER HOLDCO
Source text: ID:nBSE8phxCw
Further company coverage: ARBN.NS
(([email protected];))
July 30 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
AUROBINDO PHARMA LTD - TO BUY 100% INTEREST IN LANNETT SELLER HOLDCO
Source text: ID:nBSE8phxCw
Further company coverage: ARBN.NS
(([email protected];))
ViiV expands licence to allow generic HIV treatment production for low-income countries
By Maggie Fick
LONDON, July 14 (Reuters) - ViiV Healthcare, the HIV-focused joint venture majority owned by GSK GSK.L, said on Monday it has expanded its licensing deal with the Medicines Patent Pool to allow generic production of its long-acting injectable HIV treatment cabotegravir.
The updated licence, which builds on an earlier agreement covering cabotegravir for HIV prevention, will enable three generic drugmakers to develop and supply the treatment for use in combination with Johnson & Johnson's JNJ.N rilpivirine in 133 countries, including all low-income, lower-middle income, and Sub-Saharan African nations.
ViiV's regimen -- the only approved long-acting injectable treatment for HIV -- is administered once every one or two months, an alternative to daily pills. The World Health Organization last week recommended long-acting cabotegravir and rilpivirine as a treatment option for people who are virologically suppressed but struggle with adherence to oral regimens.
The new licence also builds on an existing Medicines Patent Pool agreement covering cabotegravir for pre-exposure prophylaxis (PrEP), signed in 2022.
The existing licensees -- Aurobindo ARBN.NS, Cipla CIPL.NS and Viatris VTRS.O -- will now be able to develop and manufacture generic versions of the long-acting treatment, subject to regulatory approvals.
"As leaders in long-acting innovation we're proud to be expanding our voluntary licence to include treatment," said ViiV CEO Deborah Waterhouse. "We're committed to working with partners like MPP to increase access and reach those most impacted by HIV."
The announcement comes after Gilead Sciences GILD.O and the Global Fund to Fight AIDS, Tuberculosis and Malaria last week finalised a separate deal to supply long-acting HIV prevention drug, lenacapavir, to low-income countries at cost -- part of a push to expand access to innovative HIV medicines in the Global South.
ViiV is majority-owned by GSK, with Pfizer PFE.N and Shionogi 4507.T as shareholders.
(Reporting by Maggie Fick. Editing by Jane Merriman)
(([email protected]; +44 7890 916706;))
By Maggie Fick
LONDON, July 14 (Reuters) - ViiV Healthcare, the HIV-focused joint venture majority owned by GSK GSK.L, said on Monday it has expanded its licensing deal with the Medicines Patent Pool to allow generic production of its long-acting injectable HIV treatment cabotegravir.
The updated licence, which builds on an earlier agreement covering cabotegravir for HIV prevention, will enable three generic drugmakers to develop and supply the treatment for use in combination with Johnson & Johnson's JNJ.N rilpivirine in 133 countries, including all low-income, lower-middle income, and Sub-Saharan African nations.
ViiV's regimen -- the only approved long-acting injectable treatment for HIV -- is administered once every one or two months, an alternative to daily pills. The World Health Organization last week recommended long-acting cabotegravir and rilpivirine as a treatment option for people who are virologically suppressed but struggle with adherence to oral regimens.
The new licence also builds on an existing Medicines Patent Pool agreement covering cabotegravir for pre-exposure prophylaxis (PrEP), signed in 2022.
The existing licensees -- Aurobindo ARBN.NS, Cipla CIPL.NS and Viatris VTRS.O -- will now be able to develop and manufacture generic versions of the long-acting treatment, subject to regulatory approvals.
"As leaders in long-acting innovation we're proud to be expanding our voluntary licence to include treatment," said ViiV CEO Deborah Waterhouse. "We're committed to working with partners like MPP to increase access and reach those most impacted by HIV."
The announcement comes after Gilead Sciences GILD.O and the Global Fund to Fight AIDS, Tuberculosis and Malaria last week finalised a separate deal to supply long-acting HIV prevention drug, lenacapavir, to low-income countries at cost -- part of a push to expand access to innovative HIV medicines in the Global South.
ViiV is majority-owned by GSK, with Pfizer PFE.N and Shionogi 4507.T as shareholders.
(Reporting by Maggie Fick. Editing by Jane Merriman)
(([email protected]; +44 7890 916706;))
Aurobindo Pharma Unit Pharmacin B.V. Merged With Its Holding Co
July 2 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
AUROBINDO PHARMA - STEPDOWN SUBSIDIARY PHARMACIN B.V. MERGED WITH ITS HOLDING CO
Source text: [ID:]
Further company coverage: ARBN.NS
(([email protected];;))
July 2 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
AUROBINDO PHARMA - STEPDOWN SUBSIDIARY PHARMACIN B.V. MERGED WITH ITS HOLDING CO
Source text: [ID:]
Further company coverage: ARBN.NS
(([email protected];;))
Aurobindo Pharma Says Curateq Biologics Receives Approval For Biosimilar Dyrupeg
June 24 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
AUROBINDO PHARMA - CURATEQ BIOLOGICS RECEIVES APPROVAL FOR BIOSIMILAR DYRUPEG FROM UK’S MHRA
Source text: [ID:]
Further company coverage: ARBN.NS
(([email protected];;))
June 24 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
AUROBINDO PHARMA - CURATEQ BIOLOGICS RECEIVES APPROVAL FOR BIOSIMILAR DYRUPEG FROM UK’S MHRA
Source text: [ID:]
Further company coverage: ARBN.NS
(([email protected];;))
Theravance Biopharma Inc. and Mylan Reach Settlement with Eugia Over YUPELRI® Patent Dispute, Allowing Generic Launch in 2039
Theravance Biopharma has reached a settlement agreement with Eugia Pharma Specialities Ltd. and its affiliates regarding ongoing patent litigation over the drug YUPELRI® (revefenacin) inhalation solution. The settlement, which resolves disputes under the Hatch-Waxman Act, grants Eugia a royalty-free, non-exclusive license to manufacture and market a generic version of the drug in the U.S. from April 23, 2039. This agreement is pending review by the U.S. Department of Justice and the Federal Trade Commission. Patent litigation with other ANDA filers, Cipla Limited and Mankind Pharma Ltd., remains ongoing.
Theravance Biopharma has reached a settlement agreement with Eugia Pharma Specialities Ltd. and its affiliates regarding ongoing patent litigation over the drug YUPELRI® (revefenacin) inhalation solution. The settlement, which resolves disputes under the Hatch-Waxman Act, grants Eugia a royalty-free, non-exclusive license to manufacture and market a generic version of the drug in the U.S. from April 23, 2039. This agreement is pending review by the U.S. Department of Justice and the Federal Trade Commission. Patent litigation with other ANDA filers, Cipla Limited and Mankind Pharma Ltd., remains ongoing.
Aurobindo Pharma Says First Us FDA Submission Planned In FY26
May 26 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
AUROBINDO PHARMA - FIRST US FDA SUBMISSION PLANNED IN FY26
AUROBINDO PHARMA - 8 BIOSIMILAR CANDIDATES WITH TAM OF GT50 BILLION USD IN 2030 UNDER DEVELOPMENT
Source text: [ID:]
Further company coverage: ARBN.NS
(([email protected];))
May 26 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
AUROBINDO PHARMA - FIRST US FDA SUBMISSION PLANNED IN FY26
AUROBINDO PHARMA - 8 BIOSIMILAR CANDIDATES WITH TAM OF GT50 BILLION USD IN 2030 UNDER DEVELOPMENT
Source text: [ID:]
Further company coverage: ARBN.NS
(([email protected];))
Indian pharma stocks drop as Trump to sign executive order to cut prices of medicines
May 12 (Reuters) - Indian pharmaceutical stocks .NIPHARM shed 1.3% on Monday, even as the broader markets rose, after U.S. President Donald Trump said he would sign an executive order to cut prescription prices to the level paid by other high-income countries, an amount he put at 30% to 80% less.
Eight of the 20 stocks on the pharmaceutical sub-index were in the red, while the benchmark Nifty 50 index .NSEI was trading 2.4% higher.
Sun Pharma, India's top drugmaker by revenue, dropped 5.4% to be the top loser on the Nifty 50 and the pharma index. Glenmark Pharma GLEN.NS and Cipla CIPL.NS declined 0.4% and 1.5%, respectively.
Trump said he would sign the executive order on Monday morning to pursue what is known as "most favored nation" pricing or international reference pricing.
The U.S. pays the most in the world for many prescription drugs, often nearly triple that of other developed nations. Trump has said he wants to close that spread, but has not publicly specified how and did not provide details.
Several Indian drugmakers get a significant chunk of their revenue from North America by selling cheaper versions of the latest drugs.
The U.S. imports nearly a third of Indian pharma products sold overseas.
India's pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.
(Reporting by Kashish Tandon in Bengaluru; Editing by Mrigank Dhaniwala)
(([email protected]; 8800437922;))
May 12 (Reuters) - Indian pharmaceutical stocks .NIPHARM shed 1.3% on Monday, even as the broader markets rose, after U.S. President Donald Trump said he would sign an executive order to cut prescription prices to the level paid by other high-income countries, an amount he put at 30% to 80% less.
Eight of the 20 stocks on the pharmaceutical sub-index were in the red, while the benchmark Nifty 50 index .NSEI was trading 2.4% higher.
Sun Pharma, India's top drugmaker by revenue, dropped 5.4% to be the top loser on the Nifty 50 and the pharma index. Glenmark Pharma GLEN.NS and Cipla CIPL.NS declined 0.4% and 1.5%, respectively.
Trump said he would sign the executive order on Monday morning to pursue what is known as "most favored nation" pricing or international reference pricing.
The U.S. pays the most in the world for many prescription drugs, often nearly triple that of other developed nations. Trump has said he wants to close that spread, but has not publicly specified how and did not provide details.
Several Indian drugmakers get a significant chunk of their revenue from North America by selling cheaper versions of the latest drugs.
The U.S. imports nearly a third of Indian pharma products sold overseas.
India's pharma exports to the U.S. jumped 16% to about $9 billion last fiscal year, according to data from government-backed trade body Pharmexcil.
(Reporting by Kashish Tandon in Bengaluru; Editing by Mrigank Dhaniwala)
(([email protected]; 8800437922;))
India's Aurobindo Pharma gains on US FDA nod for anti-cancer tablet Dasatinib
** Shares of drug maker Aurobindo Pharma ARBN.NS rise as much as 4.2% to 1,237.70 rupees
** Unit receives U.S. FDA's approval for Dasatinib tablets
** Adds, Dasatinib, used as anti-cancer medication, is expected to be launched in Q1FY26
** Stock top gainer in Nifty Pharma Index .NIPHARM which is up 1.1%
** Share price above 50-day, 100-day and 200-day exponential moving averages
** Avg rating of 25 analysts equivalent of "buy", median PT is 1,463 rupees - data compiled by LSEG
** Stock last up 4.1%, cutting YTD loss to 7.3%
(Reporting by Ashish Chandra in Bengaluru)
(([email protected] (+91 7982114624))
** Shares of drug maker Aurobindo Pharma ARBN.NS rise as much as 4.2% to 1,237.70 rupees
** Unit receives U.S. FDA's approval for Dasatinib tablets
** Adds, Dasatinib, used as anti-cancer medication, is expected to be launched in Q1FY26
** Stock top gainer in Nifty Pharma Index .NIPHARM which is up 1.1%
** Share price above 50-day, 100-day and 200-day exponential moving averages
** Avg rating of 25 analysts equivalent of "buy", median PT is 1,463 rupees - data compiled by LSEG
** Stock last up 4.1%, cutting YTD loss to 7.3%
(Reporting by Ashish Chandra in Bengaluru)
(([email protected] (+91 7982114624))
India's Aurobindo Pharma gains after US FDA nod for Rivaroxaban Tablets
** Shares of Aurobindo Pharma ARBN.NS rises 3.8% to 1123 rupees, their biggest one-day gain in over a month
** ARBN biggest gainer in the Nifty pharma index .NIPHARM, which is up 1.8%
** Drug maker gets U.S. FDA's final approval to manufacture and market Rivaroxaban Tablets USP, 2.5 mg
** Drug, which is used to treat blood clots, will be launched in Q1FY26
** Avg of analysts' rating on the stock is "Buy;" median PT is 1463 rupees - data compiled by LSEG
** Stock down 16% YTD vs 11% decline in the pharma index
(Reporting by Aleef Jahan in Bengaluru)
** Shares of Aurobindo Pharma ARBN.NS rises 3.8% to 1123 rupees, their biggest one-day gain in over a month
** ARBN biggest gainer in the Nifty pharma index .NIPHARM, which is up 1.8%
** Drug maker gets U.S. FDA's final approval to manufacture and market Rivaroxaban Tablets USP, 2.5 mg
** Drug, which is used to treat blood clots, will be launched in Q1FY26
** Avg of analysts' rating on the stock is "Buy;" median PT is 1463 rupees - data compiled by LSEG
** Stock down 16% YTD vs 11% decline in the pharma index
(Reporting by Aleef Jahan in Bengaluru)
Indian pharma stocks decline after Trump again threatens tariffs
April 9 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 1.7% on Wednesday after U.S. President Donald Trump reiterated plans to announce a "major" tariff on all pharmaceutical imports.
U.S. accounts for a third of India's overall pharma exports.
Trump also threatened the duties on Friday, after his first set of reciprocal tariffs earlier last week exempted pharma products -- a change in stance that had prompted a wild swing in pharma stocks.
On the day, all twenty constituents of the pharma index were lower, with the index dragging down the benchmark Nifty 50 .NSEI by about 0.52% as of 9:20 a.m. IST.
Gland Pharma GLAD.NS, Lupin LUPN.NS and Zydus Lifesciences ZYDU.NS were the top losers by percentage, down between 3% and 5%.
Sun Pharma SUN.NS and Cipla CIPL.NS, the top constituents by weight, fell 1.69% and 1.87%, respectively.
India's pharma exports to the U.S. mostly comprise generics, or cheaper versions of popular drugs. These currently attract almost no U.S. levies, while India imposes about 10% tax on U.S. pharma imports, according to industry experts.
The pharma index has fallen 14.4% this year.
(Reporting by Kashish Tandon and Ananta Agarwal in Bengaluru; Editing by Savio D'Souza)
(([email protected];))
April 9 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 1.7% on Wednesday after U.S. President Donald Trump reiterated plans to announce a "major" tariff on all pharmaceutical imports.
U.S. accounts for a third of India's overall pharma exports.
Trump also threatened the duties on Friday, after his first set of reciprocal tariffs earlier last week exempted pharma products -- a change in stance that had prompted a wild swing in pharma stocks.
On the day, all twenty constituents of the pharma index were lower, with the index dragging down the benchmark Nifty 50 .NSEI by about 0.52% as of 9:20 a.m. IST.
Gland Pharma GLAD.NS, Lupin LUPN.NS and Zydus Lifesciences ZYDU.NS were the top losers by percentage, down between 3% and 5%.
Sun Pharma SUN.NS and Cipla CIPL.NS, the top constituents by weight, fell 1.69% and 1.87%, respectively.
India's pharma exports to the U.S. mostly comprise generics, or cheaper versions of popular drugs. These currently attract almost no U.S. levies, while India imposes about 10% tax on U.S. pharma imports, according to industry experts.
The pharma index has fallen 14.4% this year.
(Reporting by Kashish Tandon and Ananta Agarwal in Bengaluru; Editing by Savio D'Souza)
(([email protected];))
Trump's latest tariff threat ends brief reprieve for Indian pharma stocks
By Kashish Tandon
April 4 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 4.4% on Friday, wiping out gains from the previous session, after U.S. President Donald Trump threatened steep tariffs on the sector.
"Pharma (tariffs) is going to be starting to come in, I think, at a level that you haven't really seen before," Trump told reporters aboard Air Force One.
"That will be announced in the near future, and is under review right now," Trump said.
The index was among the top sectoral losers by percentage on the benchmark Nifty 50 .NSEI, which was down about 1.2% at 11:25 a.m. IST.
All 20 constituents of the pharma index were trading in the red, with Sun Pharma SUN.NS, Dr Reddy's REDY.NS and Cipla CIPL.NS being the biggest drags.
Lupin LUPN.NS, Aurobindo Pharma ARBN. and Ipca Laboratories IPCA.NS fell about 6.5% each, and were the top losers by percentage.
Trump imposed a 10% tariff on most U.S. imports earlier this week, as well as much higher levies on dozens of rivals and allies alike, but temporarily exempted some goods, including pharmaceuticals, benefiting major exporters including India, Japan and Ireland.
Pharma stocks were a rare bright spot on Thursday as global drugmakers gained on relief that their products remained temporarily shielded from the tariffs.
However, executives and analysts had warned it was premature to celebrate as levies were still likely to come.
"If these tariffs are introduced, the manufacturers will have no choice but to pass on the impact to consumers," said Vishal Manchanda, an analyst at Systematix Institutional Equities.
Indian drugmakers have been on a 'wait and watch' mode and also raised concerns on the difficulty in setting up manufacturing in the U.S., a move that would increase their costs.
Trump in his Wednesday address had predicted pharma companies would come "roaring back" to the U.S, and warned that "they got a big tax to pay" if they don't.
(Reporting by Kashish Tandon in Bengaluru; Editing by Varun H K)
(([email protected]; 8800437922;))
By Kashish Tandon
April 4 (Reuters) - Indian pharmaceutical stocks .NIPHARM fell 4.4% on Friday, wiping out gains from the previous session, after U.S. President Donald Trump threatened steep tariffs on the sector.
"Pharma (tariffs) is going to be starting to come in, I think, at a level that you haven't really seen before," Trump told reporters aboard Air Force One.
"That will be announced in the near future, and is under review right now," Trump said.
The index was among the top sectoral losers by percentage on the benchmark Nifty 50 .NSEI, which was down about 1.2% at 11:25 a.m. IST.
All 20 constituents of the pharma index were trading in the red, with Sun Pharma SUN.NS, Dr Reddy's REDY.NS and Cipla CIPL.NS being the biggest drags.
Lupin LUPN.NS, Aurobindo Pharma ARBN. and Ipca Laboratories IPCA.NS fell about 6.5% each, and were the top losers by percentage.
Trump imposed a 10% tariff on most U.S. imports earlier this week, as well as much higher levies on dozens of rivals and allies alike, but temporarily exempted some goods, including pharmaceuticals, benefiting major exporters including India, Japan and Ireland.
Pharma stocks were a rare bright spot on Thursday as global drugmakers gained on relief that their products remained temporarily shielded from the tariffs.
However, executives and analysts had warned it was premature to celebrate as levies were still likely to come.
"If these tariffs are introduced, the manufacturers will have no choice but to pass on the impact to consumers," said Vishal Manchanda, an analyst at Systematix Institutional Equities.
Indian drugmakers have been on a 'wait and watch' mode and also raised concerns on the difficulty in setting up manufacturing in the U.S., a move that would increase their costs.
Trump in his Wednesday address had predicted pharma companies would come "roaring back" to the U.S, and warned that "they got a big tax to pay" if they don't.
(Reporting by Kashish Tandon in Bengaluru; Editing by Varun H K)
(([email protected]; 8800437922;))
FDA Says Ketamine Hydrochloride Injection Shortage Resolved As Of April 2 - Website
April 2 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
FDA SAYS KETAMINE HYDROCHLORIDE INJECTION SHORTAGE RESOLVED AS OF APRIL 2 - WEBSITE
Source text: [ID:]
Further company coverage: ARBN.NS
(([email protected];))
April 2 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
FDA SAYS KETAMINE HYDROCHLORIDE INJECTION SHORTAGE RESOLVED AS OF APRIL 2 - WEBSITE
Source text: [ID:]
Further company coverage: ARBN.NS
(([email protected];))
Aurobindo Pharma Says Acquisition In Swarnaaskshu Solar Power Expected To Be Completed By June 30
March 28 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
ACQUISITION IN SWARNAASKSHU SOLAR POWER EXPECTED TO BE COMPLETED BY JUNE 30
Source text: ID:nBSE5xtd9z
Further company coverage: ARBN.NS
(([email protected];;))
March 28 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
ACQUISITION IN SWARNAASKSHU SOLAR POWER EXPECTED TO BE COMPLETED BY JUNE 30
Source text: ID:nBSE5xtd9z
Further company coverage: ARBN.NS
(([email protected];;))
FACTBOX-Lilly's weight-loss drug launch in India to energize rivals eyeing mega market
March 20 (Reuters) - Eli Lilly LLY.N on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.
India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.
Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:
NOVO NORDISK
The Danish drugmaker NOVOb.CO had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026.
The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.
Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply. GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.
SUN PHARMA
Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.
The drugmaker said earlier this month it expects to launch the drug in the next four to five years.
BIOCON
Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.
ZYDUS LIFESCIENCES
India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.
CIPLA
Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.
Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.
DR. REDDY'S
India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.
LUPIN
India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.
NATCO, MANKIND PHARMA, AUROBINDO PHARMA
Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.
Reuters was not able to independently verify the reports.
(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)
(([email protected];))
March 20 (Reuters) - Eli Lilly LLY.N on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.
India, the world's most populous country, has high obesity rates and the second-highest number of people with type 2 diabetes. Around 11% of Indian adults are expected to become obese by 2035, according to the World Obesity Federation Atlas.
Here are the local and international drugmakers also eyeing the Indian market and looking to introduce rivals to Lilly's drug:
NOVO NORDISK
The Danish drugmaker NOVOb.CO had said it aims to launch its blockbuster weight-loss drug, Wegovy, in India by 2026.
The active ingredient in Wegovy is semaglutide, which is likely to go off-patent in 2026 in India.
Wegovy and Lilly's Mounjaro belong to the same class of treatments called GLP-1 agonists, which soared into popularity globally triggering a shortage of supply. GLP-1 drugs mimic a gut hormone that helps control blood sugar levels and slow digestion, making people feel fuller for longer.
SUN PHARMA
Sun Pharmaceutical SUN.NS, India's largest drugmaker by revenue, is developing its own GLP-1 treatment, utreglutide, for weight loss and type 2 diabetes.
The drugmaker said earlier this month it expects to launch the drug in the next four to five years.
BIOCON
Indian drugmaker Biocon BION.NS is developing its own version of Novo's Wegovy, as the drug is set to lose exclusivity next year in emerging markets such as India, Brazil, Mexico, and Saudi Arabia.
ZYDUS LIFESCIENCES
India's Zydus Lifesciences ZYDU.NS is developing the generic version of Semaglutide and plans on launching the drug after its patent expires in India.
CIPLA
Cipla CIPL.NS, India's third-largest drugmaker by sales, is among the Indian drugmakers making cheaper versions of Novo's Wegovy.
Cipla has also said it is open to partnering with Lilly to market Mounjaro in India.
DR. REDDY'S
India's Dr. Reddy's REDY.NS has said it plans to launch generic versions of Semaglutide in all the markets as Novo's patent expires.
LUPIN
India's Lupin LUPN.NS is another generic drugmaker looking to grab a share of the burgeoning obesity treatment market with its own version of Novo's Wegovy.
NATCO, MANKIND PHARMA, AUROBINDO PHARMA
Media reports say India's Natco Pharma NATP.NS, Mankind Pharma MNKI.NS, Aurobindo Pharma ARBN.NS are also developing cheaper versions of Novo's Wegovy.
Reuters was not able to independently verify the reports.
(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)
(([email protected];))
India's Aurobindo Pharma rises after facility clears US drug regulator's probe
** Shares of Aurobindo Pharma ARBN.NS rise 2.1% to 1,160.35 rupees apiece
** Drug maker's active pharmaceutical ingredients (API) manufacturing facility in southern Indian state of Telangana gets establishment inspection report from U.S. drug regulator with "voluntary action indicated" (VAI)
** A VAI classification by the U.S. drug regulator implies that the facility will not face any regulatory action
** ARBN among top gainers in pharma index .NIPHARM, which is up 0.5%
** ARBn shares are down 13% in 2025 so far compared to the 9.7% fall in the pharma index, according to exchange data
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
** Shares of Aurobindo Pharma ARBN.NS rise 2.1% to 1,160.35 rupees apiece
** Drug maker's active pharmaceutical ingredients (API) manufacturing facility in southern Indian state of Telangana gets establishment inspection report from U.S. drug regulator with "voluntary action indicated" (VAI)
** A VAI classification by the U.S. drug regulator implies that the facility will not face any regulatory action
** ARBN among top gainers in pharma index .NIPHARM, which is up 0.5%
** ARBn shares are down 13% in 2025 so far compared to the 9.7% fall in the pharma index, according to exchange data
(Reporting by Bharath Rajeswaran in Bengaluru)
(([email protected]; +91 9769003463;))
Aurobindo Pharma Says Auro Vaccines Terminates License Agreement With Hilleman Laboratories Singapore PTE
March 5 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
AUROBINDO PHARMA - TERMINATION OF LICENSE AGREEMENT WITH HILLEMAN LABORATORIES SINGAPORE PTE
AUROBINDO PHARMA - TERMINATION OF AGREEMENT BY AURO VACCINES
AUROBINDO PHARMA LTD - TERMINATION WILL NOT HAVE SIGNIFICANT IMPACT ON COMPANY FINANCIALS
Source text: ID:nnAPN2OO861
Further company coverage: ARBN.NS
(([email protected];))
March 5 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
AUROBINDO PHARMA - TERMINATION OF LICENSE AGREEMENT WITH HILLEMAN LABORATORIES SINGAPORE PTE
AUROBINDO PHARMA - TERMINATION OF AGREEMENT BY AURO VACCINES
AUROBINDO PHARMA LTD - TERMINATION WILL NOT HAVE SIGNIFICANT IMPACT ON COMPANY FINANCIALS
Source text: ID:nnAPN2OO861
Further company coverage: ARBN.NS
(([email protected];))
US aid freeze sows disruption in HIV, malaria product supply chains
USAID was major buyer of health products for poor countries
Agency spent about $600 million annually on malaria, HIV tools
Loss of predictable orders could drive up prices
Nonprofit CEO says freeze has created 'huge mess'
By Jennifer Rigby and Lisa Baertlein
LONDON, Feb 21 (Reuters) - The U.S. government's foreign aid freeze has upended the supply chain for medical products crucial for fighting diseases including HIV and malaria in some of the world's poorest countries, and life-threatening gaps could persist for months, according to two sources familiar with the sector.
The U.S. Agency for International Development (USAID) usually places around $600 million of orders annually for products such as medicines, diagnostic tests and equipment like bed nets, as part of one of its biggest health supply contracts including HIV, malaria and reproductive health.
But the freeze has put orders and forecasts, particularly those made months in advance, on hold. That will likely have far-reaching implications for deliveries, cost, and timings, according to two sources with knowledge of the global health supply chain and others working in the sector.
Companies including the U.S. firm Abbott ABT.N, Switzerland's Roche ROG.S, and India's Cipla CIPL.NS are all likely to be affected, alongside others including Hologic HOLX.O, Viatris VTRS.O, Hetero and Aurobindo ARBN.NS, the first of the sources told Reuters.
"We are monitoring the situation closely. Our highest priority is to ensure that patients have continuous access to our diagnostic tests and treatments around the world," said a Roche spokesperson in response to Reuters' questions. The other companies either declined to comment or did not respond. The U.S. State Department did not immediately respond to requests for comment.
The first source said waivers from the U.S. government, intended to allow lifesaving work to restart, only applied to orders already moving around the world. Even those were not fully functional as the USAID payment system remained down, he said. Future funding and orders were more uncertain, even for companies where the raw materials have been assembled or the manufacturing capacity booked, he added.
Medicines and diagnostic tests for HIV and malaria, as well as preventive tools like bed nets and contraceptives, could be impacted, he said.
"There will be a huge backlog," said Fitsum Lakew Alemayehu, the African Union liaison manager at WACI Health, an African advocacy organization. "In Africa, millions have been on those treatments."
'BULLWHIP' EFFECT
The dismantling of USAID has already had significant impact across the globe, including shuttering HIV clinics, stranding emergency food aid, and halting research.
For medical supplies, the freeze could also hit prices, because companies have been able to operate more efficiently knowing that they would continue to get orders from USAID, all of the sources said.
Prashant Yadav, a medical supply chain expert and senior fellow at the nonpartisan Council on Foreign Relations think tank, said the upheaval could upend this system of advance demand forecasts entirely, hitting prices and ultimately risking budget shortfalls across other buyers, like governments and global health funders.
He said it was an example of the "bullwhip" effect in supply chains, where "any small changes, even if they are for a short duration of time, get amplified at every level in the system". The term is derived from a scientific concept in which movements of a whip are amplified from the origin - the hand cracking the whip - to the endpoint.
Even if the aid freeze ends after a 90-day review, as the Trump administration originally suggested, restarting production will be complex and there could be legal issues, several experts said.
"This is a huge mess to untangle," said Tom Cotter, chief executive officer at Health Response Alliance, a nonprofit organization dedicated to ensuring equitable access to health services during emergencies.
(Reporting by Jennifer Rigby, additional reporting by Maggie Fick in London, Rishika Sadam in Hyderabad)
(([email protected];))
USAID was major buyer of health products for poor countries
Agency spent about $600 million annually on malaria, HIV tools
Loss of predictable orders could drive up prices
Nonprofit CEO says freeze has created 'huge mess'
By Jennifer Rigby and Lisa Baertlein
LONDON, Feb 21 (Reuters) - The U.S. government's foreign aid freeze has upended the supply chain for medical products crucial for fighting diseases including HIV and malaria in some of the world's poorest countries, and life-threatening gaps could persist for months, according to two sources familiar with the sector.
The U.S. Agency for International Development (USAID) usually places around $600 million of orders annually for products such as medicines, diagnostic tests and equipment like bed nets, as part of one of its biggest health supply contracts including HIV, malaria and reproductive health.
But the freeze has put orders and forecasts, particularly those made months in advance, on hold. That will likely have far-reaching implications for deliveries, cost, and timings, according to two sources with knowledge of the global health supply chain and others working in the sector.
Companies including the U.S. firm Abbott ABT.N, Switzerland's Roche ROG.S, and India's Cipla CIPL.NS are all likely to be affected, alongside others including Hologic HOLX.O, Viatris VTRS.O, Hetero and Aurobindo ARBN.NS, the first of the sources told Reuters.
"We are monitoring the situation closely. Our highest priority is to ensure that patients have continuous access to our diagnostic tests and treatments around the world," said a Roche spokesperson in response to Reuters' questions. The other companies either declined to comment or did not respond. The U.S. State Department did not immediately respond to requests for comment.
The first source said waivers from the U.S. government, intended to allow lifesaving work to restart, only applied to orders already moving around the world. Even those were not fully functional as the USAID payment system remained down, he said. Future funding and orders were more uncertain, even for companies where the raw materials have been assembled or the manufacturing capacity booked, he added.
Medicines and diagnostic tests for HIV and malaria, as well as preventive tools like bed nets and contraceptives, could be impacted, he said.
"There will be a huge backlog," said Fitsum Lakew Alemayehu, the African Union liaison manager at WACI Health, an African advocacy organization. "In Africa, millions have been on those treatments."
'BULLWHIP' EFFECT
The dismantling of USAID has already had significant impact across the globe, including shuttering HIV clinics, stranding emergency food aid, and halting research.
For medical supplies, the freeze could also hit prices, because companies have been able to operate more efficiently knowing that they would continue to get orders from USAID, all of the sources said.
Prashant Yadav, a medical supply chain expert and senior fellow at the nonpartisan Council on Foreign Relations think tank, said the upheaval could upend this system of advance demand forecasts entirely, hitting prices and ultimately risking budget shortfalls across other buyers, like governments and global health funders.
He said it was an example of the "bullwhip" effect in supply chains, where "any small changes, even if they are for a short duration of time, get amplified at every level in the system". The term is derived from a scientific concept in which movements of a whip are amplified from the origin - the hand cracking the whip - to the endpoint.
Even if the aid freeze ends after a 90-day review, as the Trump administration originally suggested, restarting production will be complex and there could be legal issues, several experts said.
"This is a huge mess to untangle," said Tom Cotter, chief executive officer at Health Response Alliance, a nonprofit organization dedicated to ensuring equitable access to health services during emergencies.
(Reporting by Jennifer Rigby, additional reporting by Maggie Fick in London, Rishika Sadam in Hyderabad)
(([email protected];))
India's Aurobindo Pharma falls after US FDA finds compliance issues at unit
** Shares of Aurobindo Pharma ARBN.NS fall 2.2% to 1,110.00 rupees, set for third straight session of losses
** US FDA classified inspection at co's unit's warehousing facility in New Jersey as 'Official Action Indicated'
** Official Action Indicated (OAI) classification indicates a facility is in an unacceptable state of compliance, per US FDA site
** The inspection, conducted from May 13-15 last year, was concluded with 5 observations
** ARBN fell 2.4% in previous session after US FDA issued five observations to subsidiary Eugia Steriles after a pre-approval inspection
** ARBN gained 23.1% in 2024
(Reporting by Vijay Malkar)
(([email protected];))
** Shares of Aurobindo Pharma ARBN.NS fall 2.2% to 1,110.00 rupees, set for third straight session of losses
** US FDA classified inspection at co's unit's warehousing facility in New Jersey as 'Official Action Indicated'
** Official Action Indicated (OAI) classification indicates a facility is in an unacceptable state of compliance, per US FDA site
** The inspection, conducted from May 13-15 last year, was concluded with 5 observations
** ARBN fell 2.4% in previous session after US FDA issued five observations to subsidiary Eugia Steriles after a pre-approval inspection
** ARBN gained 23.1% in 2024
(Reporting by Vijay Malkar)
(([email protected];))
Indian pharma stocks drop on Trump's tariff plans
Adds analyst comments in paragraphs 7 and 10, Sun Pharma MD comments in paragraph 11, updates levels
By Kashish Tandon
Feb 19 (Reuters) - An index of Indian pharmaceutical company shares .NIPHARM slid 2% to its lowest level in seven months on Wednesday after U.S. President Donald Trump said he intends to impose tariffs of about 25% or higher on pharma imports.
Twelve of the 20 stocks on the sub-index traded lower. Sun Pharma SUN.NS, India's top drugmaker by revenue, fell 2%, and Dr Reddy's REDY.NS slipped 4% to its lowest level since June.
Aurobindo Pharma ARBN.NS tumbled 6% to its lowest level in nearly a year, and Cipla CIPL.NS, India's no. 3 drugmaker, shed 2.2%.
The sub-index pared some losses and was trading 0.7% lower as of 10:44 a.m. IST.
Indian drugmakers earn a significant share of revenue from the U.S., the largest importer of Indian pharma products.
India's pharma exports to the country stood at $8.73 billion in fiscal 2024 - a nearly 16% increase from previous year - accounting for about 31% of the industry's overall exports, as per data from government-backed trade body Pharmaceuticals Export Promotion Council of India (Pharmexcil).
Trump's tariff plans are making investors jittery at the moment, as most of these companies rely on the U.S. for most of their revenue, said Shrikant Akolkar, a pharma analyst with Nuvama Institutional Equities.
The U.S. President on Tuesday told reporters that sectoral tariffs on pharmaceuticals and semiconductor chips would begin at "25% or higher", rising substantially over the course of a year, but did not provide a date for the announcement of the duties.
Trump added that he wanted to provide some time for drug and chip makers to set up U.S. factories so they could avoid tariffs.
"Even if these companies start setting up manufacturing within U.S. borders, it is a long way to go as they would need fresh approvals and also labour which is costlier in the U.S. compared to India," Akolkar said.
Earlier this week, Sun Pharma MD Dilip Shanghvi told ET Now that tariffs, if imposed, will be passed on to consumers.
Pharma stocks have lost about 12% so far this year, while the benchmark Nifty 50 .NSEI declined 4%.
(Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza and Janane Venkatraman)
(([email protected]; 8800437922;))
Adds analyst comments in paragraphs 7 and 10, Sun Pharma MD comments in paragraph 11, updates levels
By Kashish Tandon
Feb 19 (Reuters) - An index of Indian pharmaceutical company shares .NIPHARM slid 2% to its lowest level in seven months on Wednesday after U.S. President Donald Trump said he intends to impose tariffs of about 25% or higher on pharma imports.
Twelve of the 20 stocks on the sub-index traded lower. Sun Pharma SUN.NS, India's top drugmaker by revenue, fell 2%, and Dr Reddy's REDY.NS slipped 4% to its lowest level since June.
Aurobindo Pharma ARBN.NS tumbled 6% to its lowest level in nearly a year, and Cipla CIPL.NS, India's no. 3 drugmaker, shed 2.2%.
The sub-index pared some losses and was trading 0.7% lower as of 10:44 a.m. IST.
Indian drugmakers earn a significant share of revenue from the U.S., the largest importer of Indian pharma products.
India's pharma exports to the country stood at $8.73 billion in fiscal 2024 - a nearly 16% increase from previous year - accounting for about 31% of the industry's overall exports, as per data from government-backed trade body Pharmaceuticals Export Promotion Council of India (Pharmexcil).
Trump's tariff plans are making investors jittery at the moment, as most of these companies rely on the U.S. for most of their revenue, said Shrikant Akolkar, a pharma analyst with Nuvama Institutional Equities.
The U.S. President on Tuesday told reporters that sectoral tariffs on pharmaceuticals and semiconductor chips would begin at "25% or higher", rising substantially over the course of a year, but did not provide a date for the announcement of the duties.
Trump added that he wanted to provide some time for drug and chip makers to set up U.S. factories so they could avoid tariffs.
"Even if these companies start setting up manufacturing within U.S. borders, it is a long way to go as they would need fresh approvals and also labour which is costlier in the U.S. compared to India," Akolkar said.
Earlier this week, Sun Pharma MD Dilip Shanghvi told ET Now that tariffs, if imposed, will be passed on to consumers.
Pharma stocks have lost about 12% so far this year, while the benchmark Nifty 50 .NSEI declined 4%.
(Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza and Janane Venkatraman)
(([email protected]; 8800437922;))
Aurobindo Pharma Says Completion Of US FDA Pre-Approval Inspection At Eugia Steriles
Feb 18 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
COMPLETION OF US FDA PRE-APPROVAL INSPECTION AT EUGIA STERILES
INSPECTION CONCLUDES WITH 5 PROCEDURAL OBSERVATIONS
Source text: ID:nBSE3PWnk0
Further company coverage: ARBN.NS
(([email protected];;))
Feb 18 (Reuters) - Aurobindo Pharma Ltd ARBN.NS:
COMPLETION OF US FDA PRE-APPROVAL INSPECTION AT EUGIA STERILES
INSPECTION CONCLUDES WITH 5 PROCEDURAL OBSERVATIONS
Source text: ID:nBSE3PWnk0
Further company coverage: ARBN.NS
(([email protected];;))
Events:
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Dividend
Bonus
Dividend
Dividend
Dividend
Dividend
More Mid Cap Ideas
See similar 'Mid' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Aurobindo Pharma do?
Aurobindo Pharma is one of the leading vertically integrated formulations & API manufacturing companies in the world. It has a strong R&D focus and has a multi-product portfolio with manufacturing facilities in several countries. The company operates diversified businesses, structured to deliver targeted healthcare solutions across geographies and therapeutic areas. Its core operations are built on strong, integrated capabilities, encompassing both APIs and finished products. The company is one of the leading API manufacturers, with expertise in process chemistry and having the advantage of large-scale production. It is recognised globally for high-quality, reliable and cost-effective supplies. Its API business caters to both internal needs and external client demand across multiple therapeutic areas, driving profitability and sustaining the growth of its formulations area.
Who are the competitors of Aurobindo Pharma?
Aurobindo Pharma major competitors are Abbott India, Alkem Laboratories, Glenmark Pharma, Glaxosmithkline Phar, Lupin, Ipca Laboratories, Gland Pharma. Market Cap of Aurobindo Pharma is ₹62,950 Crs. While the median market cap of its peers are ₹55,105 Crs.
Is Aurobindo Pharma financially stable compared to its competitors?
Aurobindo Pharma seems to be less financially stable compared to its competitors. Altman Z score of Aurobindo Pharma is 4.58 and is ranked 8 out of its 8 competitors.
Does Aurobindo Pharma pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Aurobindo Pharma latest dividend payout ratio is 8.31% and 3yr average dividend payout ratio is 8.71%
How has Aurobindo Pharma allocated its funds?
Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments
How strong is Aurobindo Pharma balance sheet?
Balance sheet of Aurobindo Pharma is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Aurobindo Pharma improving?
The profit is oscillating. The profit of Aurobindo Pharma is ₹3,418 Crs for TTM, ₹3,486 Crs for Mar 2025 and ₹3,173 Crs for Mar 2024.
Is the debt of Aurobindo Pharma increasing or decreasing?
The net debt of Aurobindo Pharma is decreasing. Latest net debt of Aurobindo Pharma is -₹8,529.09 Crs as of Mar-25. This is less than Mar-24 when it was -₹6,241.12 Crs.
Is Aurobindo Pharma stock expensive?
Aurobindo Pharma is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Aurobindo Pharma is 18.56, while 3 year average PE is 17.35. Also latest EV/EBITDA of Aurobindo Pharma is 9.58 while 3yr average is 10.26.
Has the share price of Aurobindo Pharma grown faster than its competition?
Aurobindo Pharma has given better returns compared to its competitors. Aurobindo Pharma has grown at ~10.87% over the last 4yrs while peers have grown at a median rate of 7.98%
Is the promoter bullish about Aurobindo Pharma?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Aurobindo Pharma is 51.82% and last quarter promoter holding is 51.82%.
Are mutual funds buying/selling Aurobindo Pharma?
The mutual fund holding of Aurobindo Pharma is increasing. The current mutual fund holding in Aurobindo Pharma is 18.96% while previous quarter holding is 18.21%.